GNPX | Genprex, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.8578 - 0.9614
52 Week Range	0.2810 - 14.40
Beta	0.18
Implied Volatility	443.92%
IV Rank	100.00%
Day's Volume	339,311
Average Volume	9,590,320
Shares Outstanding	8,508,070
Market Cap	7,742,344
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-03-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.09
Forward P/E Ratio	N/A
EPS	-10.69
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	21
Country	USA
Website	GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX's peers: RVPH, GLSI, CGTX, GRCL, RVPHW, EYEN, RNAZ, KOD, EFTR, XFOR, ELEV, MREO, HEPA

*Chart delayed

Analyzing fundamentals for GNPX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see GNPX Fundamentals page.

Watching at GNPX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on GNPX Technicals page.